2026 ICD-10-CM Diagnosis Code Z79.811Long term (current) use of aromatase inhibitors

ICD-10-CM Codes›Z00–Z99›Z77-Z99›current

ICD-10-CM Z79.811
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

Z79.811 is a billable ICD-10-CM diagnosis code for long term (current) use of aromatase inhibitors. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. Coders also document this condition as long-term current use of aromatase inhibitor. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified status.

Code Identity

ICD-10-CM Code
Z79.811
Billable Status
Yes — Valid for Submission
Code Describes
Long term (current) use of aromatase inhibitors
Short Description
Long term (current) use of aromatase inhibitors
Same as the full description in the CMS dataset.
Parent Code
Z79.81
Long term (current) use of agents affecting estrogen receptors and estrogen levels

Code Classification

ChapterZ00–Z99Factors influencing health status and contact with health services
SectionZ77-Z99Persons with potential health hazards related to family and personal history and certain conditions influencing health status
CategorycurrentLong term drug therapy (Z79)
This CodeZ79.811Long term (current) use of aromatase inhibitors

Code EditsBilling

Medicare Code Editor checks that affect claim validity for Z79.811.

Unacceptable principal diagnosis
There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)Billing

Z79.811 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Long-term current use of aromatase inhibitor

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Long term (current) use of anastrozole (Arimidex)
  • Long term (current) use of exemestane (Aromasin)
  • Long term (current) use of letrozole (Femara)

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Long-term(current) (prophylactic) drug therapy (use of)
      • anastrozole (Arimidex)
    • Long-term(current) (prophylactic) drug therapy (use of)
      • aromatase inhibitors
    • Long-term(current) (prophylactic) drug therapy (use of)
      • exemestane (Aromasin)
    • Long-term(current) (prophylactic) drug therapy (use of)
      • letrozole (Femara)
    • Therapy
      • drug, long-term (current) (prophylactic)
        • anastrozole (Arimidex)
    • Therapy
      • drug, long-term (current) (prophylactic)
        • aromatase inhibitors
    • Therapy
      • drug, long-term (current) (prophylactic)
        • exemestane (Aromasin)
    • Therapy
      • drug, long-term (current) (prophylactic)
        • letrozole (Femara)

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR FAC025
Other specified status
Default principal diagnosis: inpatient No · outpatient Yes

Convert Z79.811 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
V07.52 Use aromatase inhibitors
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About Z79.811Overview

Is Z79.811 a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report long term (current) use of aromatase inhibitors on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Can Z79.811 be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because long term (current) use of aromatase inhibitors describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Is Z79.811 exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for long term (current) use of aromatase inhibitors on inpatient claims.

What is the ICD-9 equivalent of Z79.811?

Under the General Equivalence Mappings, long term (current) use of aromatase inhibitors converts to ICD-9-CM V07.52 (use aromatase inhibitors). The mapping is a direct match.